EGFR and lung carcinoma: Since erlotinib began to be used to treat lung cancer patients with EGFR mutations [1–2], about a decade ago, many new drugs have been designed to treat lung cancer patients with activating alterations at growth factor receptors with tyrosine kinase activity.